MTOR and sarcoma: Considering the patient perception of clinical benefit resulting in 20/32 (63%) of participants reporting clinical benefit, the survey findings further endorse the consensus position of the ESMO community of sarcoma experts, suggesting that the mTOR inhibitor sirolimus should be regarded as a front-line treatment for progressive EHE.